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Obesity-associated insulin resistance is
an important risk factor of type 2 diabetes
and cardiovascular diseases. In this
study, Stromsdorfer et al. demonstrate
that adipocyte-specific inactivation of
Nampt, a key NAD+ biosynthetic enzyme
known to decrease in obese rodents and
humans, causes insulin resistance in
adipose tissue, liver, and skeletal muscle.
Stromsdorfer et al., 2016, Cell Reports 16, 1851–1860
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Obesity is associatedwith adipose tissue dysfunction
and multi-organ insulin resistance. However, the
mechanisms of such obesity-associated systemic
metabolic complications are not clear. Here, we char-
acterized mice with adipocyte-specific deletion of
nicotinamide phosphoribosyltransferase (NAMPT), a
rate-limiting NAD+ biosynthetic enzyme known to
decrease in adipose tissue of obese and aged ro-
dents and people. We found that adipocyte-specific
Nampt knockout mice had severe insulin resistance
in adipose tissue, liver, and skeletal muscle and adi-
pose tissue dysfunction, manifested by increased
plasma free fatty acid concentrations and decreased
plasma concentrations of a major insulin-sensitizing
adipokine, adiponectin. Loss of Nampt increased
phosphorylation of CDK5 and PPARg (serine-273)
and decreased gene expression of obesity-linked
phosphorylated PPARg targets in adipose tissue.
These deleterious alterations were normalized by
administering rosiglitazone or a key NAD+ intermedi-
ate, nicotinamide mononucleotide (NMN). Collec-
tively, our results provide important mechanistic and
therapeutic insights into obesity-associated systemic
metabolic derangements, particularly multi-organ in-
sulin resistance.
INTRODUCTION
Obesity is associated with the development of systemic meta-
bolic complications such as multi-organ insulin resistance,
which is an important abnormality involved in the pathogenesis
of type 2 diabetes, atherogenic dyslipidemia, non-alcoholic fatty
liver disease (NAFLD), and cardiovascular disease (Reaven,
1988). Emerging evidence has suggested that adipose tissue
has the extraordinary capability of maintaining the functional
integrity of whole-body metabolic health by modulating the pro-
duction of insulin-sensitizing adipokines such as adiponectin,
pro-inflammatory cytokines and chemokines, free fatty acids
(FFAs), and other metabolites. Thus, dysfunction of adipose tis-
sue contributes to obesity-associated metabolic disorder not
only in adipose tissue but also in remote organs such as liver
and skeletal muscle (Guilherme et al., 2008; Kadowaki et al.,
2006; Perry et al., 2015; Scherer, 2006). However, the complex
mechanisms responsible for the pathogenesis of such obesity-
associated systemic metabolic complications are not still clear.
Nicotinamide adenine dinucleotide (NAD+) plays a pivotal role
in energy metabolism in a variety of organisms (Belenky et al.,
2007; Canto´ et al., 2015; Imai and Yoshino, 2013; Yoshino and
Imai, 2013). In mammals, NAD+ is synthesized from four precur-
sors: tryptophan, nicotinic acid, nicotinamide, and nicotinamide
riboside (NR). Nicotinamide phosphoribosyltransferase (NAMPT)
functions as the rate-limiting NAD+ biosynthetic enzyme and
converts nicotinamide into a key NAD+ intermediate, nicotin-
amide mononucleotide (NMN). NMN is then converted into
NAD+ by the second enzymes, nicotinamide mononucleotide
adenylyltransferases (NMNATs). NAD+ exerts pleiotropic func-
tions by modulating key NAD+-dependent metabolic regulators,
such as sirtuins and poly(ADP-ribose) polymerases (Belenky
et al., 2007; Canto´ et al., 2015; Imai and Yoshino, 2013). Studies
have revealed that NAMPT-mediated NAD+ biosynthesis in adi-
pose tissue is dynamically regulated by nutritional and environ-
mental cues. For example, adipose tissue expression of Nampt
mRNA and NAMPT protein displays a robust diurnal oscillation
pattern (Ando et al., 2005; Ramsey et al., 2009). Caloric restric-
tion markedly increases expression of Nampt mRNA and
NAMPT protein and NAD+ content in adipose tissue (Chen
et al., 2008; Song et al., 2014). In contrast, genetic or diet-
induced obesity decreases adipose tissue NAMPT and NAD+
content (Caton et al., 2011; Mercader et al., 2008; Yoshino
et al., 2011) and dampens diurnal oscillation of Nampt gene
expression (Ando et al., 2005). Aging, which is another major
risk factor of metabolic complications, also impairs NAMPT-
mediated NAD+ biosynthesis in adipose tissue (Yoshino et al.,
2011). Data obtained from studies conducted in people demon-
strate that the alterations in adipose NAMPT-mediated NAD+
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Figure 1. Adipocyte-Specific Nampt Deletion Causes Multi-organ Insulin Resistance
(A and B) Glucose metabolism in female control (flox/flox) and ANKO mice fed a standard chow. Blood glucose (A) and plasma insulin (B) concentrations during
the IPGTTs in 3- to 5-month-old mice (n = 6–8 per group). The area under the curve (AUC) for glucose is shown next to the glucose tolerance curves.
(C) Blood glucose concentrations during the ITTs in 2- to 4-month-old mice (n = 7–9 per group).
(legend continued on next page)
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biosynthesis are associated with obesity and its metabolic com-
plications (Jukarainen et al., 2016; Kovacikova et al., 2008;
Varma et al., 2007; Xu et al., 2012). For example, adipose
tissue NAMPT protein content or NAMPT gene expression is
decreased in subjects who are insulin-resistant, compared to
BMI-matched insulin-sensitive counterparts (Varma et al.,
2007; Xu et al., 2012). Contrarily, diet-induced weight loss in-
creases adipose tissue gene expression of NAMPT in people
who are overweight and obese (Kovacikova et al., 2008). These
findings suggest that NAMPT-mediated NAD+ biosynthesis in
adipose tissue is responsive to the alterations of environmental
input and could be involved in regulating whole-body glucose
metabolism. However, the physiological importance of adipose
tissue NAMPT-mediated NAD+ biosynthesis is not known. In
this study, we analyzed adipocyte-specific Nampt knockout
(ANKO) mice and tested our hypothesis that defects in
NAMPT-mediated NAD+ biosynthesis in adipocytes play a caus-
ative role in the pathogenesis of obesity-associated systemic
metabolic complications.
RESULTS
Adipocyte-Specific Deletion of Nampt Causes Severe
Insulin Resistance in Multiple Metabolic Organs
To determine themetabolic consequence induced by adipocyte-
specific Nampt deletion, we have characterized ANKO mice
generated usingNampt-floxed (flox/flox) crossedwith adiponec-
tin-Cre transgenic mice (Yoon et al., 2015). The levels of NAMPT
protein and NAD+ in visceral adipose tissue (VAT) and subcu-
taneous adipose tissue (SAT) were markedly reduced in ANKO
mice compared to flox/flox (control) mice (Yoon et al., 2015).
We evaluated glucose metabolism in control and ANKO mice
fed a regular chow diet by conducting intraperitoneal glucose
tolerance tests (IPGTTs) and insulin tolerance tests (ITTs). We
found that female ANKO mice exhibited impaired glucose toler-
ance and increased plasma insulin concentrations during the
IPGTTs compared to control mice (Figures 1A and 1B). During
the ITTs, insulin injection was not able to decrease blood glucose
concentrations in female ANKO mice (Figure 1C). Although male
ANKO mice did not exhibit impaired glucose tolerance (Fig-
ure S1A), they did have increased plasma insulin concentrations
during the IPGTTs (Figure S1B) and failed to respond to insulin
injection (Figure S1C). This disassociation of insulin tolerance
with glucose tolerance could be due to the compensatory insulin
secretion for insulin resistance. We next conducted hyperinsuli-
nemic-euglycemic clamp procedures (HECPs). The glucose
infusion rate in ANKOmice was markedly lower than that in con-
trol mice (Figure 1D), even though ANKO mice had slightly
increased blood glucose and insulin concentrations (Figures
S1D and S1E). ANKO mice demonstrated a failure of insulin to
suppress hepatic glucose production (HGP), whereas control
mice suppressed HGP by 90% during the HECP (Figures 1E
and 1F). Insulin clearance rate, another indicator of hepatic
insulin sensitivity, was also lower in ANKO mice than in control
mice (ANKO = 66.2 ± 5.0; control = 89.0 ± 7.4 ml/kg lean body
weight/min; p < 0.05). Supporting our in vivo observation,
ANKO mice had increased hepatic gene expression of key glu-
coneogenic enzymes, such as glucose-6-phosphatase (G6pc)
and pyruvate dehydrogenase kinase 4 (Pdk4), compared to
control mice (Figure 1G). In addition, whole-body insulin-medi-
ated glucose disposal rates were reduced by 18% in ANKO
mice (Figure 1H), and this was accompanied by reduction in
glycolysis rates (Figure S1F). Consistently, insulin-stimulated
glucose uptake in gastrocnemius muscle and heart was reduced
by 64% and 50%, respectively (Figure 1I). Despite such severe
multi-organ insulin resistance, ANKO mice had similar total
body weight, body composition, oxygen consumption, carbon
dioxide production, and respiratory exchange ratio compared
to control mice (Figures S1G and S1H). Altogether, these results
demonstrate that adipocyte-specific deletion of Nampt causes
severe multi-organ insulin resistance, independent of whole-
body adiposity and body weight.
Loss of Nampt Causes Adipose Tissue Dysfunction
These findings of systemic insulin resistance prompted us to
hypothesize that the defects in NAMPT-mediated NAD+ bio-
synthesis impair adipose tissue metabolic pathways that can
influence whole-body glucose metabolism. Insulin-stimulated
glucose uptake in VAT was reduced by 60% in ANKO mice
compared to control mice (Figure 2A). Similarly, ANKO mice
showed impaired insulin-mediated suppression of plasma
FFA concentrations (Figures 2B and 2C). The insulin-stimulated
AKT phosphorylation (serine-473) was also reduced by 70% in
VAT obtained from ANKO mice compared to control mice
(Figure 2D). In addition, ANKOmice had increased plasma con-
centrations of FFA and triglyceride (TG) (Figures 2E and S2A)
and increased hepatic TG content (Figure 2F). We next asked
whether these deleterious alterations are accompanied by
adipose tissue inflammation, a hallmark of obesity and its
metabolic complications (Guilherme et al., 2008; Scherer,
2006). VAT gene expression of inflammatory markers was upre-
gulated in ANKO mice compared to control mice (Figure 2G).
Immunodetection of the macrophage-specific antigen F4/80
also suggested increased adipose tissuemacrophage accumu-
lation in ANKO mice (Figure S2B). However, plasma concentra-
tions of major pro-inflammatory cytokines and chemokines
were not different between ANKO and control mice (Fig-
ure S2C). ANKO mice did not display altered gene expression
of several inflammatory markers in liver (Figure S2D), suggest-
ing that adipocyte-specific Nampt deletion causes local adi-
pose tissue inflammation but not systemic inflammation. In
contrast, plasma concentrations of key adipokines that regulate
(D–I) HECP was performed in 3- to 8-month-old mice (n = 9–10 per group). (D) Glucose infusion rate (GIR) during the HECP. Average of GIR during the clamp
period is shown next to the GIR curves. (E) Basal and insulin-stimulated rates of HGP. (F) Insulin-stimulated percent suppression of basal HGP. (G) Hepatic gene
expression of gluconeogenic enzymes,G6pc and Pdk4, after the HECP (n = 6–7 per group). (H) Whole-body glucose disposal rates. (I) Insulin-stimulated glucose
uptake in skeletal muscle and heart.
Values are mean ± SE. The p values were determined by Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001.
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hepatic and skeletal muscle insulin sensitivity and glucose ho-
meostasis, adiponectin and adipsin (Kadowaki et al., 2006;
Scherer, 2006), were markedly reduced in ANKO mice (Figures
2H and S2E). Altogether, these findings demonstrate that loss
of Nampt impairs key adipose tissue functions, which could
contribute to the development of systemic metabolic complica-
tions in ANKO mice.
ANKO Mice Have Increased Phosphorylation of CDK5
and PPARg and Decreased Gene Expression of Obesity-
Linked Targets, Including Adiponectin and Adipsin, in
Adipose Tissue
Increased serine-273 (Ser273) phosphorylation of the nuclear
receptor peroxisome proliferator-activated receptor gamma
(PPARg) has been found to impair its activity toward a subset
Figure 2. Loss of Nampt Induces Adipose Tissue Dysfunction
(A) Adipose tissue function in female control and ANKO mice. Insulin-stimulated glucose uptake in VAT during the HECP (n = 9–10 per group).
(B and C) Plasma FFAs concentrations in basal and insulin-stimulated conditions (B) and insulin-stimulated percent suppression during the HECP (C) (n = 6–7 per
group).
(D) Western blot and quantification of phosphorylated AKT (serine-473) and total AKT in VAT obtained after the HECP (n = 5–7 per group).
(E) Plasma FFA and TG concentrations at a fed condition in 4- to 5-month-old mice (n = 7–9 per group).
(F) Hepatic TG concentrations in 2- to 9-month-old mice (n = 15–16 per group).
(G) VAT gene expression of inflammatory markers in 4-month-old mice (n = 4 per group). Il6, interleukin 6; Tnf, tumor necrosis factor; Mcp-1, monocyte
chemoattractant protein 1; Cd68, CD68 antigen.
(H) Plasma concentrations of adiponectin and adipsin in 2- to 3-month-old mice (n = 6–11 per group).
Values are mean ± SE. The p values were determined by Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001.
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of its target genes involved in regulating whole-body glucose
metabolism, including a key insulin-sensitizing adipokine, adipo-
nectin. Thus, it is implicated in the pathophysiology of obesity-
associated insulin resistance (Banks et al., 2015; Choi et al.,
2010, 2011, 2014a, 2014b). ANKO mice had increased protein
content of phosphorylated PPARg (Ser273) in VAT compared
to control mice (Figure 3A). Phosphorylation of cyclin-dependent
kinase 5 (CDK5), a critical regulator of PPARg phosphorylation at
Ser273 (Banks et al., 2015; Choi et al., 2010, 2011), was also
increased in VAT from ANKO mice (Figure 3B). Pharmacological
inhibition of the NAD+-dependent protein deacetylase SIRT1
significantly increased CDK5 phosphorylation in OP9 adipocytes
(Figure S3A), indicating SIRT1 could be one key mediator of
NAMPT-mediated NAD+ biosynthesis in regulating phosphoryla-
tion of CDK5. In addition, VAT from ANKO mice displayed
increased lysine acetylation of PPARg (Figure 3C), indicating
that hyperacetylation of PPARg could also be involved in the
observed increase in PPARg phosphorylation (Mayoral et al.,
2015; Qiang et al., 2012). We next evaluated VAT expression of
obesity-linked target genes that are known to be the most sensi-
tive to PPARg phosphorylation (Ser273) (Choi et al., 2010).
Nampt deletion caused significant changes in adipose tissue
gene expression in 9 of 12 (75%) of these targets, including adi-
ponectin and adipsin (Figure 3D). Loss of Nampt similarly
affected gene expression of these targets in SAT (Figure S3B).
In contrast, ANKO mice did not display alterations in classical
PPARg lipogenic gene targets (Figure S3C). Six weeks of PPARg
agonist rosiglitazone (RSG) administration (20 mg/kg body
weight/day) improved insulin sensitivity and decreased plasma
insulin concentrations in ANKO mice (Figures 3E and 3F). RSG
treatment also restored gene expression of key obesity-linked
PPARg targets, including adiponectin and adipsin, in VAT and
SAT (Figure 3G) and increased plasma concentrations of adipo-
nectin and adipsin (Figure 3H). In contrast, RSG treatment did
not change body weight, food intake, body temperature, loco-
motor activity, hypothalamic NAD+ concentrations, and putative
RSG targets in liver and skeletal muscle (Figures 3I and S3D–
S3I), although it is still possible that RSG affected other untested
metabolic pathways. Consistent with in vivo observation, a
potent NAMPT inhibitor, FK866, reduced adiponectin and adip-
sin gene expression in OP9 adipocytes, and pharmacological
inhibition of CDK5 with MRL24 reversed these FK866-induced
alterations (Figure 3J). Altogether, these data suggest that
increased phosphorylation of CDK5 and PPARg (Ser273) are,
at least in part, responsible for the metabolic derangements
induced by adipocyte-specific Nampt deletion.
NMN, a Key NAD+ Intermediate, Normalizes Metabolic
Derangements in ANKO Mice
To determine whether metabolic derangements depend on the
defects in NAD+ biosynthesis in ANKO mice, we treated mice
with NMN, a key NAD+ intermediate and the product of the
NAMPT reaction (Figure 4A). In this experiment, female ANKO
mice were given drinking water containing NMN (500 mg/kg
body weight/day), and metabolic parameters were evaluated af-
ter 4–6 weeks of NMN treatment. We determined this dosage
based on our previous study (Yoshino et al., 2011). NMN admin-
istration significantly increased adipose tissue NAD+ concentra-
tions in ANKO mice (Figure 4B). NMN administration improved
insulin sensitivity in ANKO mice compared to the age-matched
untreated ANKO mice (Figure 4C). The insulin responses in
NMN-treated ANKO mice were similar to those in the age-
matched control mice, suggesting that NMN administration
normalized the insulin resistance phenotype. NMN administra-
tion also normalized plasma insulin and FFA concentrations in
ANKO mice (Figures 4D and 4E). However, NMN did not change
body weight (ANKO = 18.1 ± 0.4; NMN-treated ANKO = 18.0 ±
0.5 g), daily food intake (ANKO = 0.22 ± 0.01; NMN-treated
ANKO = 0.21 ± 0.01 g/g of body weight), or body temperature
(ANKO = 36.7 ± 0.2; NMN-treated ANKO = 36.7 ± 0.3C) during
this relatively short period of treatment. NMN administration
decreased phosphorylation of PPARg (Ser273) and CDK5 in
VAT (Figures 4F and 4G). In addition, NMN-treated ANKO mice
reduced global nuclear lysine acetylation (Figures 4H and S4A),
indicating that NMN administration could increase activity of
nuclear NAD+-dependent protein deacetylases such as SIRT1.
Adipose tissue gene expression and plasma concentrations of
adiponectin and adipsin were restored by NMN administration
(Figures 4I and 4J). In addition, we confirmed that adipose tissue
expressed nicotinic acid phosphoribosyltransferase (NAPRT)
(Figure S4B) and tested the effect of 5- to 7-week administration
of nicotinic acid (NA) (500mg/kg bodyweight/day), the precursor
in the NAPRT-dependent NAD+ biosynthetic pathway (Fig-
ure 4A). Treatment with NA also normalized the metabolic de-
rangements in ANKO mice (Figures S4C–S4G). Although we
cannot exclude the possibility that the beneficial effects of NA
treatment are partly mediated by the G protein-coupled recep-
tors (PUMA-G) (Tunaru et al., 2003) and/or other metabolic path-
ways or organs, these results from NMN and NA treatment sup-
port our conclusion that NAMPT-mediated NAD+ biosynthesis
in adipocytes is an important physiological regulator of adipose
tissue and whole-body metabolic function.
DISCUSSION
In this study, we provide compelling evidence for the importance
of adipose NAMPT-mediated NAD+ biosynthesis in regulating
whole-body metabolic function. Our results demonstrate that
adipocyte-specific Nampt deletion (1) induces adipose tissue
dysfunction, characterized by decreased production of key adi-
pokines (namely adiponectin and adipsin), increased plasma
FFA availability, and local adipose tissue inflammation; (2) causes
severe insulin resistance in adipose tissue, liver, and skeletalmus-
cle without concomitant increases in body weight or whole-body
adiposity; and (3) increases phosphorylation of CDK5 and PPARg
(Ser273) while markedly reducing gene expression of obesity-
linked specific targets of phosphorylated PPARg, which include
adiponectin and adipsin. Furthermore, these deleterious meta-
bolic alterations were completely normalized by administering
PPARg agonist RSG, key NAD+ intermediate NMN, or NAD+ pre-
cursor NA. These results provide important insight into under-
standing the mechanisms of obesity-associated systemic meta-
bolic complications, including adipose tissue dysfunction and
multi-organ insulin resistance.
This study demonstrates that defects in adipose NAMPT-
mediated NAD+ biosynthesis induce various obesity-associated
Cell Reports 16, 1851–1860, August 16, 2016 1855
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systemic metabolic complications, including severe multi-organ
insulin resistance. Previous studies have demonstrated that ge-
netic ablation of adiponectin or its receptor or receptors results
in the impairment of the ability of insulin to suppress glucose pro-
duction in liver, and to stimulate glucose utilization in skeletal
muscle, and that hypoadiponectinemia is related to the degree
of insulin resistance in people (Kadowaki et al., 2006; Scherer,
2006). In addition, it has been shown that excessive plasma
FFA availability or increased adipose tissue lipolysis can cause
insulin resistance in liver and skeletal muscle (Guilherme et al.,
2008; Perry et al., 2015). Therefore, it is likely that adipocyte-spe-
cific Nampt deletion causes insulin resistance in remote meta-
bolic organs through hypoadiponectinemia and/or excessive
FFA release from adipose tissue. It is also possible that the alter-
ations in circulating extracellular NAMPT (eNAMPT) affect
neuronal metabolic signals associated with hypothalamus and
are involved in the pathogenesis of systemic metabolic compli-
cations observed in ANKO mice (Imai and Yoshino, 2013; Yoon
et al., 2015). Given previous findings demonstrating that reduc-
tion in adipose NAMPT expression and NAD+ content is associ-
ated with obesity and its metabolic complications in people and
rodents (Ando et al., 2005; Jukarainen et al., 2016; Kovacikova
et al., 2008; Mercader et al., 2008; Xu et al., 2012; Yoshino
et al., 2011), our data strongly suggest that impaired NAMPT-
mediated NAD+ biosynthesis in adipose tissue plays a causative
role in the pathophysiology of obesity-associated metabolic de-
rangements and thus could be an important therapeutic target.
Studies have shown that systemic administration of NAD+ inter-
mediates, such as NMN and NR, improves insulin resistance,
dyslipidemia, NAFLD, and glucose intolerance in obese mice
(Canto´ et al., 2012, 2015; Gariani et al., 2016; Imai and Yoshino,
2013; Yoshino et al., 2011). Although adipose tissue functionwas
not extensively examined in these studies, it is likely that
enhancing adipose NAD+ biosynthesis mediates such metabolic
beneficial effects in obesemice. Additional studies are needed to
determine whether enhancing NAD+ biosynthesis in adipocytes
alone is sufficient to counteract the systemic negative effects
of obesity on glucose metabolism.
A series of studies has established that PPARg is an important
regulator of adipocyte metabolism and a molecular target for
the treatment of obesity-associated metabolic complications
(Lehrke and Lazar, 2005). Post-translational modifications play
a critical role in regulating PPARg function, and evidence shows
that increased phosphorylation (Ser273) leads to a selective
deactivation of PPARg toward a subset of its target genes
involved in whole-body glucose metabolism, including the key
adipokines adiponectin and adipsin (Banks et al., 2015; Choi
et al., 2010, 2011, 2014a, 2014b). Our results demonstrate that
NAD+ could be an important endogenous physiological regulator
of PPARg in adipocytes. The precise mechanisms by which
NAMPT-mediated NAD+ biosynthesis regulates phosphorylation
of PPARg at Ser273 remain unclear. Our results suggest that
NAMPT-mediated NAD+ biosynthesis could regulate phosphor-
ylation of CDK5, an important regulator of PPARg phosphoryla-
tion (Banks et al., 2015; Choi et al., 2010, 2011), possibly through
the modulation of SIRT1 activity. Given previous findings sug-
gesting that hyperacetylation of PPARg at lysines 293 also leads
to an increase in Ser273 phosphorylation (Qiang et al., 2012), it is
likely that NAMPT-mediated NAD+ biosynthesis and SIRT1
together regulate PPARg Ser273 phosphorylation bymodulating
CDK5 phosphorylation and PPARg acetylation. Consistent with
this idea, adipocyte-specific Sirt1 knockout mice have increased
acetylation and Ser273 phosphorylation of PPARg in adipose tis-
sue (Mayoral et al., 2015). In addition, several independent
groups have reported that adipocyte-specific Sirt1 knockdown
or knockout is causatively related to adipose tissue dysfunction
and systemic metabolic complications (Chalkiadaki and Guar-
ente, 2012; Gillum et al., 2011; Mayoral et al., 2015). Nonethe-
less, we cannot exclude the possibility that other sirtuins and
NAD+-consuming enzymes, such as poly(ADP-ribose) polymer-
ases (Belenky et al., 2007; Canto´ et al., 2015; Imai and Yoshino,
2013), also mediate effects induced by the defects in NAMPT-
mediated NAD+ biosynthesis in ANKO mice.
In conclusion, this provides important insight into understand-
ing the extraordinary functional capability of adipose tissue
to regulate whole-body glucose metabolism. Although future
Figure 3. ANKOMice Have Increased Phosphorylation of CDK5 and PPARg and Decreased Gene Expression of Obesity-like Phosphorylated
PPARg Targets in Adipose Tissue
(A and B) Protein levels of phosphorylated PPARg (Ser273) (A) and CDK5 (B) in VAT obtained from 2- to 3-month-old female control and ANKO mice after
overnight fasting. Phosphorylated protein levels were normalized by total protein content.
(C) Immunoprecipitated acetylated PPARg and PPARg (inputs) were evaluated in VAT. Acetylated PPARg levels were normalized by PPARg protein content (n = 4
per group).
(D) VAT gene expression of obesity-liked phosphorylated PPARg targets in female control and ANKOmice (n = 4 per group).Cidec, cell death-inducing DFFA-like
effector c; Car3, carbonic anhydrase 3; Cyp2f2, cytochrome P450, family 2, subfamily f, polypeptide 2; Selebbp1, selenium binding protein 1; Txnip, thioredoxin
interacting protein; Nr3c1, nuclear receptor subfamily 3, group C, member 1; Nr1d1, nuclear receptor subfamily 1, group D, member 1; Nr1d2, nuclear receptor
subfamily 1, group D, member 2; Acly, ATP citrate lyase; Aplp2, amyloid beta (A4) precursor-like protein 2.
(E) Female ANKOmice received a chow containing RSG (20mg/kg body weight/day). ITTs were performed after 6 weeks of RSG treatment. ITT results fromRSG-
treated and age-matched untreated ANKO mice were shown (n = 7–12 per group). The area under the curve (AUC) for glucose is shown next to the insulin
tolerance curves.
(F) Plasma insulin concentrations in RSG-treated and RSG-untreated ANKO mice (n = 7–10 per group).
(G) VAT and SAT gene expression of obesity-liked PPARg (Ser273) targets in RSG-treated and RSG-untreated ANKO mice (n = 4–7 per group).
(H) Plasma concentrations of adiponectin and adipsin in RSG-treated and RSG-untreated female ANKO mice (n = 7–12 per group).
(I) Total number of ambulations and instances of vertical rearing in RSG-treated and RSG-untreatedmale ANKOmice on the 1 hr locomotor test (n = 5 per group).
(J) OP9 adipocytes were cultured with 0.1%DMSO (control), 500 nM FK866, or FK866 plus 30 nMMRL24 (CDK5 inhibitor) for 48 hr and examined for adiponectin
and adipsin gene expression (n = 3 per group).
Values aremean ± SE. The p values were determined by Student’s t test. (A) p < 0.05 (control versus FK866); (B) p < 0.05 (FK866 versus FK866+MRL24) (ANOVA).
*p < 0.05; **p < 0.01; ***p < 0.001.
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studies are required to determine the effects of genetic and phar-
macological activation of adipocyte NAMPT-mediated NAD+
biosynthesis on phosphorylation of CDK5 and PPARg andmeta-
bolic function in obese rodents, it would be of great interest to
examine whether enhancing NAD+ biosynthesis in adipocytes
provides an effective intervention against obesity-induced
Figure 4. NMN, a Key NAD+ Intermediate, Normalizes Metabolic Derangements in ANKO Mice
(A) Mammalian NAD+ biosynthetic pathways. NMN is a product of NAMPT-mediated enzymatic reaction, and it is directly converted into NAD+. NA is a precursor
for the NAPRT-dependent NAD+ biosynthetic pathway. NIC, nicotinmaide; Trp, tryptophan; NaMN, nicotinic acid mononucleotide.
(B) Female ANKOmice were given drinking water containing NMN (500mg/kg body weight/day). Adipose tissue NAD+ concentrations were determined in female
ANKO mice after 4–6 weeks of treatment of NMN and untreated ANKO mice (n = 5–7 per group).
(C) ITTs were performed after 4 weeks of treatment of NMN. ITT results from NMN-treated mice (n = 7), age-matched 2- to 3-month-old untreated ANKO mice
(n = 14), and control mice (n = 8) were shown. The area under the curve (AUC) for glucose is shown next to the insulin tolerance curves.
(D and E) Plasma concentrations of insulin (D) and FFA (E) in NMN-treated, NMN-untreated ANKO, and control mice (n = 5–11 per group).
(F–H) Phosphorylated PPARg (Ser273) (F), phosphorylated CDK5 (G), and lysine acetylation of nuclear proteins (H) in VAT obtained from NMN-treated and NMN-
untreated ANKO mice (n = 3–4 per group).
(I) VAT gene expression of obesity-liked PPARg (Ser273) targets in NMN-treated and untreated ANKO mice (n = 4–5 per group).
(J) Plasma concentrations of adiponectin and adipsin in NMN-treated and NMN-untreated ANKO mice (n = 5–12 per group).
Values are mean ± SE. *p < 0.05; **p < 0.01; ***p < 0.001 (NMN-treated ANKO versus NMN-untreated ANKO, Student’s t test). (A) p < 0.05 (NMN-treated versus
NMN-untreated ANKO); (B) p < 0.05 (control versus NMN-untreated ANKO) (ANOVA).
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multi-organ metabolic derangements without the unfavorable
side effect profile associated with PPARg agonists.
EXPERIMENTAL PROCEDURES
Animal Experimentation
ANKO mice were generated by using adiponectin-Cre transgenic mice and
floxed-Nampt mice as previously described (Yoon et al., 2015). Mice were
maintained on a standard chow diet (LabDiet 5053; LabDiet) ad libitum. For
RSG rescue experiments, ANKO mice received a chow containing RSG
(#71740; Cayman Chemical) at the approximate dose of 20 mg/kg body
weight/day soon after weaning for up to 7 weeks. For NAD+ precursor rescue
experiments, we administered NMN (#44500900; Oriental Yeast) and NA
(#72309; Sigma-Aldrich) in drinking water, at the approximate dose of
500 mg/kg of body weight, to ANKO mice soon after weaning for up to
2 months. All animal studies were approved by the Washington University
Animal Studies Committee.
Hyperinsulinemic-Euglycemic Clamp Study
The hyperinsulinemic-euglycemic clamp study was carried out by the Univer-
sity of Michigan Animal Phenotyping Core with modified procedures. See
details in the Supplemental Experimental Procedures.
Real-Time PCR
Gene expression was determined as previously described (Yoshino et al.,
2011). See details in the Supplemental Experimental Procedures.
Western Blot
Frozen tissue samples were rapidly homogenized in ice-cold lysis buffer.
Nuclear protein was extracted by using the Nuclear Extraction kit (#SK-
0001; Signosis). Antibodies and other details are available in the Supplemental
Experimental Procedures.
NAD+ Measurement
NAD+ concentrations were determined using a high performance liquid chro-
matography (HPLC) system (Prominence; Shimadzu) with a Supelco LC-18-T
column (#58970-U; Sigma-Aldrich) as described previously (Yoon et al., 2015;
Yoshino and Imai, 2013; Yoshino et al., 2011).
Cell Culture
OP9 mouse stromal cells were provided by Dr. Nathan Wolins (Wolins et al.,
2006). See details in the Supplemental Experimental Procedures.
Statistical Analyses
Differences between two groups were assessed using Student’s paired or un-
paired t test. Comparisons among three groups were performed using one-
way ANOVA with the Tukey’s post hoc test. The p values of less than 0.05
were considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.07.027.
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